1. Açık Erişim@BUU
  2. İndeksli Yayınlar
  3. Web of Science
Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız: http://hdl.handle.net/11452/25660
Başlık: Rituximab as a new therapeutic option in granulomatosis with polyangiitis: A report of two cases
Yazarlar: Kamalı, Sevil
Uludağ Üniversitesi/İç Hastalıkları Anabilim Dalı/Romatoloji Bölümü.
Dalkılıç, Ediz
Alkış, Nihan
6506739457
26533912000
Anahtar kelimeler: Rheumatology
Rituximab
Granulomatosis with polyangiitis
Ocular involvement
Wegeners-granulomatosis
Vasculitis
Cyclophosphamide
Methotrexate
Efficacy
Trial
Yayın Tarihi: Tem-2012
Yayıncı: Taylor & Francis
Atıf: Dalkılıç, E. vd. (2012). "Rituximab as a new therapeutic option in granulomatosis with polyangiitis: A report of two cases". Modern Rheumatology, 22(3), 463-466.
Özet: Findings of several reports suggest that rituximab, a chimeric monoclonal anti-CD20 antibody causing B-lymphocyte depletion, might represent a treatment option for people with granulomatosis with polyangiitis (GPA) (former Wegener's granulomatosis). This study presents the results of rituximab treatment in two patients with treatment-refractory GPA. First patient received rituximab for a granulomatous posterior orbital mass lesion, and eye symptoms were resolved after three courses of treatment. The second patient had eye and paranasal sinus involvement and benefited from two courses of rituximab treatment, with significant clinical improvement. Rituximab may represent an effective novel treatment for remission induction in GPA.
URI: https://doi.org/10.1007/s10165-011-0507-7
https://www.tandfonline.com/doi/abs/10.3109/s10165-011-0507-7
http://hdl.handle.net/11452/25660
ISSN: 1439-7595
1439-7609
Koleksiyonlarda Görünür:Scopus
Web of Science

Bu öğenin dosyaları:
Bu öğeyle ilişkili dosya bulunmamaktadır.
Tüm Öğe Kaydını Göster İstatistikler


DSpace'deki bütün öğeler, aksi belirtilmedikçe, tüm hakları saklı tutulmak şartıyla telif hakkı ile korunmaktadır.